Core Viewpoint - Maide Medical announced that its 2025 semi-annual performance briefing is scheduled for September 10, 2025 [1] Company Summary - The company is preparing to hold a performance briefing to discuss its financial results for the first half of 2025 [1]

证券代码：688310 证券简称：迈得医疗 公告编号：2025-035 迈得医疗工业设备股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 3 日（星期三）至 9 月 9 日（星期二）16:00 前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 （zq@maiderchina.com）进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 迈得医疗工业设备股份有限公司（以下简称"公司"）已于 2025 年 8 月 28 日 发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 9 月 10 日（星期三）10:00-11:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 三、 参加人员 董事长、总经理：林军华先生 一、 说明会类型 本次投资者说明会以 ...

Core Viewpoint - The stock of Maide Medical (688310) has shown significant volatility, with a recent increase in price and notable trading activity, indicating potential investor interest and market dynamics [1][2]. Trading Information Summary - Maide Medical's stock reached a closing price of 19.67 yuan as of August 29, 2025, up 6.21% from the previous week, with a peak price of 21.3 yuan on August 26, marking a near one-year high [1]. - The stock was listed on the Shanghai and Shenzhen Stock Exchanges' "Dragon and Tiger List" on August 26 due to a 15% increase in closing price, marking its first appearance in five trading days [2][6]. Shareholder Changes Summary - As of June 30, 2025, the number of shareholders for Maide Medical was 3,805, a decrease of 192 (4.8%) from March 31, 2025, with the average shareholding per account increasing from 41,600 shares to 43,700 shares [3][6]. Performance Disclosure Summary - The mid-year report for 2025 indicated a main revenue of 141 million yuan, a year-on-year decrease of 14.75%, and a net profit attributable to shareholders of 6.0451 million yuan, down 38.81% [4]. - In the second quarter of 2025, the company reported a main revenue of 101 million yuan, an increase of 10.58% year-on-year, and a net profit attributable to shareholders of 16.8424 million yuan, a significant increase of 2,759.64% [4][6]. - The company reported a debt ratio of 28.37%, with investment income of 174,600 yuan and financial expenses of -819,100 yuan, alongside a gross profit margin of 38.93% [4]. Company Announcement Summary - On August 26, 2025, Maide Medical held its fifth supervisory board meeting, where it approved the half-year report and a special report on the use of raised funds, with unanimous agreement [5][6].

Group 1 - The stock price of Maide Medical (688310) closed at 18.74 yuan on August 28, 2025, down 2.55% with a turnover rate of 5.95% and a trading volume of 98,900 hands, resulting in a transaction amount of 191 million yuan [1] - The net inflow of main funds on August 28 was 1.2183 million yuan, accounting for 0.64% of the total transaction amount, while retail investors had a net inflow of 1.2535 million yuan, also accounting for 0.65% [1] - The company reported a main business income of 141 million yuan for the first half of 2025, a year-on-year decrease of 14.75%, and a net profit attributable to shareholders of 6.0451 million yuan, down 38.81% year-on-year [4] Group 2 - The financing data on August 28 showed a financing balance of 87.245 million yuan, with a net repayment of 15.0958 million yuan [2] - The company’s total market value is 3.115 billion yuan, with a net asset of 828 million yuan and a net profit of 6.0451 million yuan, ranking 202nd, 198th, and 185th respectively in the specialized equipment industry [4] - The gross profit margin of Maide Medical is 38.93%, which is higher than the industry average of 27.56% [4]

Core Insights - The recent financial report of Maide Medical (688310) shows a decline in total revenue and net profit for the first half of 2025 compared to the previous year, with total revenue at 141 million yuan, down 14.75%, and net profit at 6.0451 million yuan, down 38.81% [1] - However, the second quarter of 2025 saw a recovery with total revenue of 101 million yuan, an increase of 10.58%, and net profit of 16.8424 million yuan, a significant rise of 2759.64% year-on-year [1] - The company has a high accounts receivable ratio, with accounts receivable accounting for 42.42% of total revenue [1] Financial Performance - Total revenue for 2024 was 165 million yuan, while for 2025 it decreased to 141 million yuan, reflecting a decline of 14.75% [1] - Net profit for 2024 was 9.8799 million yuan, which fell to 6.0451 million yuan in 2025, a decrease of 38.81% [1] - The gross profit margin decreased to 38.93% in 2025 from 48.04% in 2024, a drop of 18.96% [1] - The net profit margin turned negative at -1.29% in 2025, down from 4.27% in 2024, a decline of 130.24% [1] - Total expenses (selling, administrative, and financial) amounted to 48.8283 million yuan, accounting for 34.63% of revenue, a slight increase of 0.71% year-on-year [1] Investment and Market Position - The company has a significant amount of accounts receivable, which decreased to 117 million yuan in 2025 from 140 million yuan in 2024, a decline of 16.79% [1] - The company’s return on invested capital (ROIC) has been historically variable, with a median ROIC of 12.63% since its listing, but a poor performance in 2024 with an ROIC of -3.64% [3] - Maide Medical's competitive advantage in the domestic contact lens market lies in its comprehensive R&D system, which integrates multiple disciplines and has over 20 years of technical accumulation [5] - The company is positioned in a market dominated by international players, but its shorter delivery times compared to larger Taiwanese OEMs may provide a competitive edge [5] Fund Holdings - The largest fund holding Maide Medical is the Guotai Juhua Value Open Mixed Fund, which holds 200,000 shares and has recently entered the top ten holdings [4] - The fund has a scale of 273 million yuan and a recent net value increase of 0.49% [4]

Financial Performance - The total revenue for Maide Medical in the 2025 mid-year report was 141 million yuan, a decrease of 14.75% year-on-year [1] - The net profit attributable to the parent company was 6.05 million yuan, down 38.81% year-on-year [1] - In Q2 2025, total revenue was 101 million yuan, an increase of 10.58% year-on-year, while net profit reached 16.84 million yuan, a significant increase of 2759.64% [1] - The gross profit margin was 38.93%, a decrease of 18.96% year-on-year, and the net profit margin was -1.29%, down 130.24% year-on-year [1] - The total of selling, administrative, and financial expenses was 48.83 million yuan, accounting for 34.63% of revenue, a slight increase of 0.71% year-on-year [1] - The earnings per share were 0.04 yuan, a decrease of 33.33% year-on-year, while the operating cash flow per share was 0.68 yuan, an increase of 241.93% year-on-year [1] Industry Context - The domestic contact lens market is dominated by four major international players: Johnson & Johnson, CooperVision, Alcon, and Bausch + Lomb [5] - The contact lens industry in mainland China is still in its early development stage, with domestic production primarily relying on Taiwanese manufacturers for processing [5] - Maide Medical has a competitive advantage due to its 20 years of technical accumulation in equipment, forming a comprehensive R&D system across multiple disciplines [5] - The company’s technological capabilities in materials science, mechanics, and various manufacturing processes provide a synergistic advantage in the contact lens business, allowing for shorter delivery cycles compared to larger Taiwanese manufacturers [5] Investment Insights - The company has shown a historical median ROIC of 12.63%, indicating good investment returns, although the worst year was 2024 with a ROIC of -3.64% [3] - The largest fund holding Maide Medical is the Guotai Juhua Value Open Mixed Fund, which has a scale of 273 million yuan and has seen a 10.14% increase over the past year [4]

Core Insights - The company reported a revenue of 141 million yuan and a net profit attributable to shareholders of 6.0451 million yuan for the first half of 2025, with a significant increase in net cash flow from operating activities by 243.9% year-on-year [1] - In the second quarter, the company achieved a revenue of 101 million yuan and a net profit of 16.8424 million yuan, marking a substantial turnaround from previous losses [1] Business Overview - The main business of the company includes the research, production, sales, and service of medical consumables and intelligent equipment, focusing on safety infusion and blood purification devices [1] - The company is actively expanding its second growth curve through its subsidiary, Zhejiang Maide Shun Contact Lens Co., Ltd., by advancing its contact lens business and developing related materials and products [1] Production Capacity and Strategy - The company currently operates four production lines for contact lenses, each with an annual capacity of 18 million pieces, and plans to dynamically adjust production capacity based on market conditions as the business commercializes [2] - The company has a unique advantage in production, as it manufactures its own equipment, allowing for continuous improvement and cost optimization, unlike competitors who must purchase equipment [2] Order and Contract Status - As of the end of 2024, the company has 21 orders for its drug-device combination products, which are expected to be a new growth point for performance [2] - The company's contract liabilities exceeded 180 million yuan in the first half of the year, representing an increase of 83.28% compared to the end of the previous year, indicating a rise in advance payments for orders [2]

Core Viewpoint - The company, Maider Medical, reported significant growth in revenue and net profit for the first half of 2025, driven by increased R&D investment and a strong market demand for medical consumables, indicating a positive outlook for future performance [1][2]. Financial Performance - In the first half of 2025, the company achieved operating revenue of 141 million yuan and a net profit attributable to shareholders of 3.18 million yuan, with a non-recurring net profit of 6.05 million yuan [1]. - R&D investment reached 17.98 million yuan, accounting for 12.75% of operating revenue, an increase of 0.48 percentage points compared to previous periods [1]. - The net cash flow from operating activities was 113 million yuan, a year-on-year increase of 243.90% [1]. Market Position and Demand - The domestic medical consumables market is experiencing a recovery, with increasing demand and continuous technological innovations driving industry growth [1][2]. - The company's contract liabilities reached 181 million yuan, a significant year-on-year increase of 83.28%, indicating a strong order backlog and market recognition of its products [1][3]. Technological Advancements - Maider Medical integrates various technologies in medical device production, providing automated solutions that enhance efficiency and quality in the manufacturing of medical consumables [3][4]. - The company has developed key technologies in automated production, achieving domestic leadership in several areas and addressing critical technical challenges [3][6]. R&D and Innovation - The company emphasizes continuous R&D, with 36 new patent applications and 85 new patent grants in the first half of 2025, totaling 501 approved patents [6]. - The R&D team comprises 109 personnel, representing 17.38% of the total workforce, reflecting the company's commitment to innovation [5][6]. Market Expansion - Maider Medical is actively expanding into the contact lens market, targeting a projected market size of over 20 billion yuan by 2025, with a focus on enhancing domestic supply capabilities [7][8]. - The company has established production lines with an annual capacity of 18 million pieces each and plans to adjust production based on market feedback [8]. Strategic Vision - The company aims to become a global leader in medical consumables automation, focusing on technological advancements and exploring high-value medical equipment markets [9].

1.1本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到www.sse.com.cn网站仔细阅读半年度报告全文。 1.2重大风险提示 公司已在本报告中详细阐述经营过程中可能面临的风险及应对措施，有关内容敬请查阅第三节"管理层 讨论与分析"之"四、风险因素"。敬请投资者予以关注，审慎作出投资决定。 1.3本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司代码：688310 公司简称：迈得医疗 第一节 重要提示 □适用 √不适用 第二节 公司基本情况 2.1公司简介 公司股票简况 ■ 公司存托凭证简况 1.4公司全体董事出席董事会会议。 1.5本半年度报告未经审计。 1.6董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 1.7是否存在公司治理特殊安排等重要事项 □适用 √不适用 联系人和联系方式 2.4前十名境内存托凭证持有人情况表 ■ 2.2主要财务数据 单位：元 币种：人民币 ■ 2.3前10名股东持股情况表 单位: 股 ■ □适用 ...

Core Insights - The financing balance of the Sci-Tech Innovation Board increased by 1.9 billion yuan compared to the previous trading day, marking a continuous increase for 33 trading days [1] - The total margin balance reached 218 billion yuan, with a financing balance of 217.25 billion yuan and a securities lending balance of 755 million yuan [1] - The stocks with the highest financing balances include SMIC at 11 billion yuan, followed by Cambrian and Haiguang Information at 9.2 billion yuan and 7.2 billion yuan respectively [1] Financing Balance Summary - 270 stocks saw an increase in financing balance, while 314 stocks experienced a decrease [1] - Notable increases in financing balance were observed in Maide Medical (41.95%), Jingyi Equipment (32.05%), and Anbotong (28.86%) [1][2] - Significant decreases were noted in Yifang Bio (-29.85%), Kangwei Century (-21.02%), and Jushi Chemical (-20.70%) [1][2] Securities Lending Balance Summary - The highest securities lending balance was recorded for Cambrian at 48 million yuan, followed by Haiguang Information and SMIC at 39 million yuan and 32 million yuan respectively [2] - 117 stocks saw an increase in securities lending balance, while 158 stocks experienced a decrease [2] - The largest increases in securities lending balance were in Bairen Medical (299.55%), Jucheng Technology (127.31%), and Yihua Tong (112.52%) [2] - The largest decreases were in Tianzhihang (-54.20%), Diaomicro (-50.23%), and Funeng Technology (-46.69%) [2]